LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration Small Mol Conc Unit LJP Library Plate Replicate Assay Well Timepoint Timepoint Unit Total Cell Count Before Treatment Total Cell Count After Treatment Total Control Cell Count Relative Cell Count Relative Growth Rate After Treatment
MDA-MB-231 QL-XII-47
3.33
uM
LJP6
 2
O20
 72
hr
 868 956 3486 0.2742 0.0336
MDA-MB-231 QL-XII-47
3.33
uM
LJP6
 3
O20
 72
hr
 868 862 3486 0.2473 -0.0023
MDA-MB-231 Radicicol
3.33
uM
LJP5
 1
K08
 72
hr
 868 957 3486 0.2745 0.0339
MDA-MB-231 Radicicol
3.33
uM
LJP5
 2
K08
 72
hr
 868 1279 3486 0.3669 0.1569
MDA-MB-231 Radicicol
3.33
uM
LJP5
 3
K08
 72
hr
 868 1101 3486 0.3158 0.0889
MDA-MB-231 Radicicol
3.33
uM
LJP6
 1
K08
 72
hr
 868 1264 3486 0.3626 0.1512
MDA-MB-231 Radicicol
3.33
uM
LJP6
 2
K08
 72
hr
 868 1315 3486 0.3772 0.1707
MDA-MB-231 Radicicol
3.33
uM
LJP6
 3
K08
 72
hr
 868 1253 3486 0.3594 0.1470
MDA-MB-231 Seliciclib
3.33
uM
LJP5
 1
J02
 72
hr
 868 2594 3486 0.7440 0.6592
MDA-MB-231 Seliciclib
3.33
uM
LJP5
 2
J02
 72
hr
 868 2581 3486 0.7403 0.6542
MDA-MB-231 Seliciclib
3.33
uM
LJP5
 3
J02
 72
hr
 868 2699 3486 0.7742 0.6993
MDA-MB-231 Ruxolitinib
3.33
uM
LJP5
 1
O14
 72
hr
 868 3140 3486 0.9006 0.8677
MDA-MB-231 Ruxolitinib
3.33
uM
LJP5
 2
O14
 72
hr
 868 3506 3486 1.0056 1.0075
MDA-MB-231 Ruxolitinib
3.33
uM
LJP5
 3
O14
 72
hr
 868 3273 3486 0.9388 0.9185
MDA-MB-231 XL147
3.33
uM
LJP5
 1
G08
 72
hr
 868 3545 3486 1.0168 1.0224
MDA-MB-231 XL147
3.33
uM
LJP5
 2
G08
 72
hr
 868 3541 3486 1.0157 1.0209
MDA-MB-231 XL147
3.33
uM
LJP5
 3
G08
 72
hr
 868 3748 3486 1.0750 1.0999
MDA-MB-231 Saracatinib
3.33
uM
LJP6
 1
D08
 72
hr
 868 2455 3486 0.7042 0.6061
MDA-MB-231 Saracatinib
3.33
uM
LJP6
 2
D08
 72
hr
 868 2111 3486 0.6055 0.4747
MDA-MB-231 Saracatinib
3.33
uM
LJP6
 3
D08
 72
hr
 868 2149 3486 0.6164 0.4892
MDA-MB-231 Selumetinib
3.33
uM
LJP6
 1
M08
 72
hr
 868 1610 3486 0.4618 0.2834
MDA-MB-231 Selumetinib
3.33
uM
LJP6
 2
M08
 72
hr
 868 1705 3486 0.4890 0.3196
MDA-MB-231 Selumetinib
3.33
uM
LJP6
 3
M08
 72
hr
 868 1709 3486 0.4902 0.3212
MDA-MB-231 Sirolimus
3.33
uM
LJP6
 1
L14
 72
hr
 868 2669 3486 0.7656 0.6878
MDA-MB-231 Sirolimus
3.33
uM
LJP6
 2
L14
 72
hr
 868 2885 3486 0.8275 0.7703